



Cyclacel Pharmaceuticals, Inc.  
Investor Relations Department  
200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

**NASDAQ: CYCC** <sup>1</sup>

Last Trade:	1.74
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.71 - 10.90
Volume	N/A
Market Cap. (\$M)	11.206
Shares Out (M)	6.440

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Jul 21, 2017*  
[Cyclacel Announces Closing of \\$15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option](#)
- Jul 19, 2017*  
[Cyclacel Announces Pricing of \\$13.2 Million Underwritten Public Offering](#)
- May 11, 2017*  
[Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results](#)
- May 5, 2017*  
[Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results](#)
- Apr 4, 2017*  
[Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

- Mar 31, 2017*  
[Annual Report \(10-K\)](#)
- Apr 12, 2017*  
[Definitive Proxy Statement](#)
- May 12, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 11, 2016*  
[Quarterly Report \(10-Q\)](#)